Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q2

2342.TEDINET S100PJSQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥5.5bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥12.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥6.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥135m2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥1.6bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥204m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥1.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.5bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥157m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥1.5bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥55m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥982m2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥55m2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥976m2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥10.7bnat 2022-09-30Cons.Assets
Total assets¥10.4bnat 2022-03-31Cons.Assets
Total assets¥10.4bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.0bnat 2022-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥6.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.6bnat 2022-03-31Cons.Net assets
Net assets / equity¥5.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥4.6bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥3.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow−¥696m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥883m2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥601m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥982m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥238m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥65m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥320m2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥3.262022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥56.562021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.522021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥56.42021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio60.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥111m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥153m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥187,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥92m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥246m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥6m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥6m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥97m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥261,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥1.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Provision for loss on order received clPrior1YearInstant148000JPY
Provision for loss on order received clCurrentQuarterInstant－JPY
Other clPrior1YearInstant158932000JPY
Other clCurrentQuarterInstant141046000JPY
Current liabilitiesPrior1YearInstant2659423000JPY
Current liabilitiesCurrentQuarterInstant3020584000JPY
Bonds payablePrior1YearInstant151000000JPY
Bonds payableCurrentQuarterInstant144000000JPY
Long term loans payablePrior1YearInstant880560000JPY
Long term loans payableCurrentQuarterInstant767104000JPY
Long term accounts payable otherPrior1YearInstant43697000JPY
Long term accounts payable otherCurrentQuarterInstant35630000JPY
Net defined benefit liabilityPrior1YearInstant24762000JPY
Net defined benefit liabilityCurrentQuarterInstant38698000JPY
Other nclPrior1YearInstant44484000JPY
Other nclCurrentQuarterInstant36560000JPY
Noncurrent liabilitiesPrior1YearInstant1144504000JPY
Noncurrent liabilitiesCurrentQuarterInstant1021993000JPY
LiabilitiesPrior1YearInstant3803928000JPY
LiabilitiesCurrentQuarterInstant4042578000JPY
Capital stockPrior1YearInstant50000000JPY
Capital stockCurrentQuarterInstant50000000JPY
Capital surplusPrior1YearInstant4109106000JPY
Capital surplusCurrentQuarterInstant3869990000JPY
Retained earningsPrior1YearInstant2657874000JPY
Retained earningsCurrentQuarterInstant2611859000JPY
Treasury stockPrior1YearInstant-300325000JPY
Treasury stockCurrentQuarterInstant-76915000JPY
Shareholders equityPrior1YearInstant6516656000JPY
Shareholders equityCurrentQuarterInstant6454935000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1066000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant1814000JPY
Foreign currency translation adjustmentPrior1YearInstant14851000JPY
Foreign currency translation adjustmentCurrentQuarterInstant26191000JPY
Valuation and translation adjustmentsPrior1YearInstant15918000JPY
Valuation and translation adjustmentsCurrentQuarterInstant28005000JPY
Subscription rights to sharesPrior1YearInstant200000JPY
Subscription rights to sharesCurrentQuarterInstant200000JPY
Non controlling interestsPrior1YearInstant104007000JPY
Non controlling interestsCurrentQuarterInstant134346000JPY
Net assetsPrior1YearInstant6636782000JPY
Net assetsCurrentQuarterInstant6617487000JPY
Liabilities and net assetsPrior1YearInstant10440710000JPY
Liabilities and net assetsCurrentQuarterInstant10660065000JPY
Net salesPrior1YTDDuration6702129000JPY
Net salesCurrentYTDDuration5542343000JPY
Cost of salesPrior1YTDDuration4138139000JPY
Cost of salesCurrentYTDDuration4430836000JPY
Gross profitPrior1YTDDuration2563989000JPY
Gross profitCurrentYTDDuration1111507000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass